Cargando…

Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain

Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Young-Hwan, Kim, Yeo Ok, Kang, Koon Mook, Lee, Hyung Gon, Son, Borum, Han, Xuehao, Oh, Eunseok, Kim, Siwon, Seo, Seon Hee, Park, Jong-Hyun, Park, Ki Duk, Kim, Woong Mo, Yoon, Myung Ha, Kim, Yong-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030932/
https://www.ncbi.nlm.nih.gov/pubmed/35455404
http://dx.doi.org/10.3390/ph15040407
_version_ 1784692265150578688
author Jung, Young-Hwan
Kim, Yeo Ok
Kang, Koon Mook
Lee, Hyung Gon
Son, Borum
Han, Xuehao
Oh, Eunseok
Kim, Siwon
Seo, Seon Hee
Park, Jong-Hyun
Park, Ki Duk
Kim, Woong Mo
Yoon, Myung Ha
Kim, Yong-Chul
author_facet Jung, Young-Hwan
Kim, Yeo Ok
Kang, Koon Mook
Lee, Hyung Gon
Son, Borum
Han, Xuehao
Oh, Eunseok
Kim, Siwon
Seo, Seon Hee
Park, Jong-Hyun
Park, Ki Duk
Kim, Woong Mo
Yoon, Myung Ha
Kim, Yong-Chul
author_sort Jung, Young-Hwan
collection PubMed
description Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, 17, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC(50) values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound 17 showed partial agonism (EC(50) = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound 17 showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain.
format Online
Article
Text
id pubmed-9030932
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90309322022-04-23 Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain Jung, Young-Hwan Kim, Yeo Ok Kang, Koon Mook Lee, Hyung Gon Son, Borum Han, Xuehao Oh, Eunseok Kim, Siwon Seo, Seon Hee Park, Jong-Hyun Park, Ki Duk Kim, Woong Mo Yoon, Myung Ha Kim, Yong-Chul Pharmaceuticals (Basel) Article Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, 17, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC(50) values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound 17 showed partial agonism (EC(50) = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound 17 showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain. MDPI 2022-03-27 /pmc/articles/PMC9030932/ /pubmed/35455404 http://dx.doi.org/10.3390/ph15040407 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jung, Young-Hwan
Kim, Yeo Ok
Kang, Koon Mook
Lee, Hyung Gon
Son, Borum
Han, Xuehao
Oh, Eunseok
Kim, Siwon
Seo, Seon Hee
Park, Jong-Hyun
Park, Ki Duk
Kim, Woong Mo
Yoon, Myung Ha
Kim, Yong-Chul
Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_full Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_fullStr Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_full_unstemmed Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_short Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
title_sort development of dibenzothiazepine derivatives as multifunctional compounds for neuropathic pain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030932/
https://www.ncbi.nlm.nih.gov/pubmed/35455404
http://dx.doi.org/10.3390/ph15040407
work_keys_str_mv AT jungyounghwan developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT kimyeook developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT kangkoonmook developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT leehyunggon developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT sonborum developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT hanxuehao developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT oheunseok developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT kimsiwon developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT seoseonhee developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT parkjonghyun developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT parkkiduk developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT kimwoongmo developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT yoonmyungha developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain
AT kimyongchul developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain